Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | Future directions of CAMILLA trial

Anwaar Saeed, MD, University of Kansas Medical Center, Kansas City, MO, discusses the future directions of the CAMILLA trial (NCT03539822). The current stage of the trial is a Phase II multicohort study, looking at the efficacy of cabozantinib plus durvalumab in gastric, esophageal, and colorectal cancer. An additional cohort is looking at the triplet regimen of cabozantinib plus durvalumab plus tremelimumab for patients with hepatocellular carcinoma, building on the results from the HIMALAYA trial (NCT03298451). This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.